Company Overview

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies derived from pluripotent stem cells. The company operates within the biotechnology and regenerative medicine industries, with a primary emphasis on treatments for ophthalmologic and neurologic disorders that currently lack effective therapies. Lineage’s programs are designed to replace or support cells that are lost or dysfunctional due to disease or injury.

The company’s primary value drivers are its proprietary cell therapy platforms and clinical-stage product candidates, most notably its retinal pigment epithelium cell therapy for geographic atrophy. Lineage targets highly specialized patient populations within the retinal disease and central nervous system markets. Its strategic positioning centers on scalable, standardized allogeneic cell therapies that can be manufactured in advance and delivered without patient-specific customization. Lineage was formed in 2019 through a strategic separation from BioTime, Inc., consolidating BioTime’s cell therapy assets into a single, publicly traded entity focused exclusively on clinical development.

Business Operations

Lineage operates through integrated research, development, and clinical operations, advancing multiple cell therapy programs through preclinical and clinical stages. Its core business units are organized around therapeutic areas, including ophthalmology programs and neurological programs, with resources allocated based on clinical progress and regulatory milestones. The company does not currently generate product revenue and instead relies on capital markets funding, collaboration revenue, and grants to support operations.

The company controls proprietary stem cell lines, differentiation technologies, and manufacturing processes used to produce its therapeutic candidates. A key subsidiary, Cell Cure Neurosciences Ltd., based in Israel, plays a central role in the development of Lineage’s ophthalmology programs and conducts a significant portion of its research and clinical activities. Lineage has also entered into strategic partnerships and licensing agreements with larger pharmaceutical companies to support development, manufacturing, or commercialization in select markets.

Strategic Position & Investments

Lineage’s strategic direction prioritizes advancing its most clinically mature programs toward late-stage development while selectively investing in earlier-stage assets with high unmet medical need. A central growth initiative is the continued development of OpRegen, its retinal pigment epithelium cell therapy for geographic atrophy secondary to age-related macular degeneration. The company has pursued capital-efficient development through partnerships, including global collaboration agreements that provide upfront payments, research funding, and potential milestone payments.

The company’s investments are concentrated in proprietary cell therapy platforms rather than broad acquisition activity. Lineage maintains full or majority ownership of its key programs while leveraging external manufacturing and commercialization capabilities where appropriate. Emerging areas of focus include next-generation cell delivery methods and expansion of its allogeneic platform into additional neurodegenerative and ophthalmic indications, subject to clinical and regulatory validation.

Geographic Footprint

Lineage is headquartered in the United States, with principal executive offices in California, and maintains a meaningful international presence through subsidiaries and clinical operations. Its most significant non-U.S. operations are in Israel, where Cell Cure Neurosciences Ltd. conducts research, development, and clinical trial activities, particularly for ophthalmology programs.

The company’s clinical trials and strategic collaborations extend across North America, Europe, and the Middle East, reflecting its intention to pursue regulatory approvals and commercialization in multiple major healthcare markets. While Lineage does not yet have commercial operations, its global clinical and partnership footprint positions it for future international market entry pending successful trial outcomes.

Leadership & Governance

Lineage is led by an executive team with experience in biotechnology, regenerative medicine, and public company governance. The leadership’s stated strategic vision emphasizes scientific rigor, disciplined capital allocation, and the advancement of cell therapies with clear regulatory and commercial pathways. Governance is overseen by a board of directors with expertise in life sciences, finance, and corporate strategy.

Key executives include:

• Brian M. Culley – President and Chief Executive Officer
• Mark R. Gilbert – Chief Financial Officer
• Carl F. Neumann, Ph.D. – Chief Development Officer
• Michael D. West, Ph.D. – Founder and Chief Scientific Advisor

The leadership team focuses on building long-term value through clinical execution, strategic partnerships, and adherence to regulatory and ethical standards in cell therapy development.